We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


LeukoDx, GE Healthcare Enter Agreement

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

LeukoDx and GE Healthcare’s have announced that they have entered into an agreement to address topics in cell characterization for cell therapy manufacturing. Under the terms of this agreement, LeukoDx will develop for GE Healthcare, technology aimed at simplifying and expediting the process of cell characterization during cell therapy manufacturing.

Further details of the agreement were not disclosed. Production of cell-based therapies varies in key ways from biomanufacturing processes. Time pressure to generate the therapeutic cell dose is far greater while working with smaller volumes and numbers of unique and precious cells. This raises new and specific requirements on characterization of cells to become and be maintained as therapeutically relevant.

Julien Meissonnier, President and CEO of LeukoDx, commented: “This agreement with GE opens exciting possibilities for us. It is a great opportunity to harness our experience and technology we have established in the diagnostic market with Accelix and leverage them for cell therapy manufacturing.

The recent achievements in cancer treatment start to address some of the most severe diseases of our time. LeukoDx is excited to be part of the team to make these therapies successful and to be there for patients at the diagnosis as well as the production of their personalized therapies. We’re looking forward to working with GE, and to further help the dynamic and fast-moving biopharmaceutical industry meet its ongoing challenges.”

Phil Vanek, GM of Cell Therapy Technologies at GE Healthcare’s Life Sciences business said, “GE is focused on reliable, scaled-out manufacturing workflows that enable successful commercialization of cell therapies. Improved tools need to allow manufacturers to get information about the cells at every step of the process.

Applying our deep knowledge and experience in cell bioprocessing to develop start-to-finish solutions, we hope to support the cell therapy industry’s goal of safely and effectively treating patients suffering from devastating diseases such as cancer.”